Literature DB >> 19141073

AZD2184: a radioligand for sensitive detection of beta-amyloid deposits.

Allan E Johnson1, Fredrik Jeppsson, Johan Sandell, David Wensbo, Jan A M Neelissen, Anders Juréus, Peter Ström, Henrietta Norman, Lars Farde, Samuel P S Svensson.   

Abstract

The presence of beta-amyloid plaques in brain is a hallmark of Alzheimer's disease (AD) and serves as a biomarker for confirmation of diagnosis postmortem. Positron emission tomography (PET) radioligands such as Pittsburgh compound B ([(11)C]-2-(3-fluoro-4-methylamino-phenyl)-benzothiazol-6-ol) (PIB) binds selectively to beta-amyloid and are promising new tools supporting the clinical diagnoses of AD. In addition, such methodology may be useful for evaluation of new drugs aiming at reduction of amyloid plaque load. The objective of this study is to develop a new amyloid selective PET radioligand with higher signal-to-background ratio when compared with existing amyloid PET ligands. The lead compound, AZD2184, (2-[6-(methylamino)pyridin-3-yl]-1,3-benzothiazol-6-ol) was found to have high affinity for amyloid fibrils in vitro (K(d): 8.4 +/- 1.0 nM). Two minutes after i.v. administration in rats, about 1% of the dose was in brain. In vitro autoradiography on cortical brain sections from amyloid-beta precursor protein/presenilin 1 (APP/PS1) mice and AD patients showed that while [(3)H]AZD2184 and [(3)H]PIB are mutually displaceable, [(3)H]AZD2184 displays a higher signal-to-background ratio primarily by virtue of lower background binding levels. The ratio of binding ability in prefrontal cortex (high plaque load) to subcortical white matter (background) was 4.5 for [(3)H]AZD2184 and 0.8 for [(3)H]PIB at 1 nM. In adjacent cortical sections from APP/PS1 mouse as well as from AD cortical tissue, [(3)H]AZD2184 and antibodies to human beta-amyloid labeled identical structures. In vivo administration of [(3)H]AZD2184 to APP/PS1 mice further showed that [(3)H]AZD2184 labels amyloid deposits with low non-specific background binding. Taken together, the pre-clinical profile of AZD2184 in relation to the reference ligand PIB, suggests that (11)C-labeled AZD2184 is a potential radioligand for PET-visualization of beta-amyloid deposits in the living human brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141073     DOI: 10.1111/j.1471-4159.2008.05861.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  34 in total

1.  Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains.

Authors:  Masahiro Ono; Shun Hayashi; Kenji Matsumura; Hiroyuki Kimura; Yoko Okamoto; Masafumi Ihara; Ryosuke Takahashi; Hiroshi Mori; Hideo Saji
Journal:  ACS Chem Neurosci       Date:  2011-03-21       Impact factor: 4.418

Review 2.  Quantum dots and prion proteins: is this a new challenge for neurodegenerative diseases imaging?

Authors:  Pavlina Sobrova; Iva Blazkova; Jana Chomoucka; Jana Drbohlavova; Marketa Vaculovicova; Pavel Kopel; Jaromir Hubalek; Rene Kizek; Vojtech Adam
Journal:  Prion       Date:  2013-09-20       Impact factor: 3.931

3.  18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.

Authors:  Hank F Kung; Seok Rye Choi; Wenchao Qu; Wei Zhang; Daniel Skovronsky
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

4.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Kewei Chen; Jessica B S Langbaum; Adam S Fleisher; Napatkamon Ayutyanont; Cole Reschke; Wendy Lee; Xiaofen Liu; Dan Bandy; Gene E Alexander; Paul M Thompson; Norman L Foster; Danielle J Harvey; Mony J de Leon; Robert A Koeppe; William J Jagust; Michael W Weiner; Eric M Reiman
Journal:  Neuroimage       Date:  2010-03-02       Impact factor: 6.556

5.  Synthesis and In Vitro Evaluation of Imidazo[1,2-b]pyridazines as Ligands for β-Amyloid Plaques.

Authors:  Fanxing Zeng; David Alagille; Gilles D Tamagnan; Brian J Ciliax; Allan I Levey; Mark M Goodman
Journal:  ACS Med Chem Lett       Date:  2010-03-11       Impact factor: 4.345

6.  Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328.

Authors:  Scott T Harrison; James Mulhearn; Scott E Wolkenberg; Patricia J Miller; Stacey S O'Malley; Zhizhen Zeng; David L Williams; Eric D Hostetler; Sandra Sanabria-Bohórquez; Linda Gammage; Hong Fan; Cyrille Sur; J Christopher Culberson; Richard J Hargreaves; Jacquelynn J Cook; George D Hartman; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2011-04-18       Impact factor: 4.345

Review 7.  Positron emission tomography radioligands for in vivo imaging of Aβ plaques.

Authors:  N Scott Mason; Chester A Mathis; William E Klunk
Journal:  J Labelled Comp Radiopharm       Date:  2013 Mar-Apr       Impact factor: 1.921

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

9.  Pittsburgh Compound-B (PiB) binds amyloid β-protein protofibrils.

Authors:  Ghiam Yamin; David B Teplow
Journal:  J Neurochem       Date:  2016-12-12       Impact factor: 5.372

10.  Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

Authors:  Svante Nyberg; Maria Eriksdotter Jönhagen; Zsolt Cselényi; Christer Halldin; Per Julin; Hans Olsson; Yvonne Freund-Levi; Jan Andersson; Katarina Varnäs; Samuel Svensson; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.